Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Sold by Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD decreased its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 33.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 348,173 shares of the company’s stock after selling 178,585 shares during the period. Cellebrite DI comprises 1.8% of Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD’s portfolio, making the stock its 20th largest holding. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD’s holdings in Cellebrite DI were worth $7,664,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Cellebrite DI by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company’s stock valued at $7,202,000 after buying an additional 75,092 shares during the last quarter. Telemark Asset Management LLC purchased a new position in shares of Cellebrite DI in the third quarter valued at $6,736,000. Two Sigma Advisers LP boosted its stake in shares of Cellebrite DI by 9.8% in the third quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock valued at $22,584,000 after purchasing an additional 120,000 shares during the period. Harbor Capital Advisors Inc. boosted its stake in shares of Cellebrite DI by 65.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company’s stock valued at $3,473,000 after purchasing an additional 62,320 shares during the period. Finally, State Street Corp boosted its stake in Cellebrite DI by 7.3% during the 3rd quarter. State Street Corp now owns 443,700 shares of the company’s stock valued at $7,472,000 after acquiring an additional 30,052 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Up 2.7 %

Shares of NASDAQ CLBT opened at $17.23 on Wednesday. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30. The company has a market cap of $3.55 billion, a price-to-earnings ratio of -12.40, a price-to-earnings-growth ratio of 4.27 and a beta of 1.53. The firm’s 50-day simple moving average is $21.67 and its 200 day simple moving average is $19.72.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, equities analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Cellebrite DI in a research note on Monday. Lake Street Capital increased their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI has an average rating of “Buy” and a consensus price target of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.